Executive Director, Biostatistics

About Us

Kardigan is a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world.

It is Kardigan’s mission to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases to the cures they deserve.

Led by Tassos Gianakakos, Jay Edelberg, M.D., Ph.D., and Bob McDowell, Ph.D., Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020.

We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients.

At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals. Driven by patients and their families , we are deeply committed to improving the lives of patients and prioritizing their needs above all else. We believe in being authentic —leading with truth to bring out the best in others by creating an environment where every person knows they will be fully accepted. With an eagerness to learn , we encourage the highest levels of curiosity and are open to changing our minds. We are committed to winning as a team with urgency, excellence, and intention, and support each other no matter what role we play or where we sit. Lastly, we strive to enable the impossible because patients are counting on us. We are not afraid to take risks to unlock innovation and advance scientific discoveries.

These values are the foundation of our work, empowering us to make a real difference, every day.

Department: Biometrics

Reports To: VP, Biometrics

Location On-site: Princeton, NJ or South San Francisco, CA — 4 days per week

Direct Reports: Biostatistics Program Leads

Role Mandate: The Executive Director, Head of Biostatistics will serve as Kardigan’s principal statistical authority, leading regulatory strategy, late-stage development decision-making, and the continued growth of a highly influential Biostatistics organization supporting multiple registration-directed cardiovascular programs.

Position Summary:

The Executive Director, Head of Biostatistics is the scientific, strategic, and operational leader of Kardigan’s Biostatistics function. Reporting to the VP, Biometrics, this individual serves as the principal statistical authority across the organization — shaping program strategy, owning regulatory interactions, and driving analytical excellence from late-phase development through NDA submission and beyond.

This is a scientific leadership role, not a coordination function. The incumbent must command credibility with clinical, medical, regulatory, and executive leadership; bring bold, regulatorily credible ideas to program design and analytical strategy; and hold the Biostatistics function to a standard of proactivity and influence that directly shapes program outcomes.

The ideal candidate has been through the full arc of late-phase development — from study design through NDA filing and FDA interaction — and brings the precision medicine methodology depth, regulatory gravitas, and cross-functional leadership capability that Kardigan’s pipeline demands.

Essential Duties and Responsibilities

· Serve as Kardigan’s senior statistical leader and principal authority on biostatistical strategy across a portfolio of late-stage cardiovascular development programs advancing toward regulatory submission.

· Shape clinical development strategy by influencing study design, endpoint selection, estimand frameworks, evidence-generation plans, and key development decisions from protocol concept through NDA submission.

· Lead regulatory statistical strategy and serve as the primary statistical representative in interactions with FDA and other health authorities, including briefing packages, regulatory meetings, submission support, and responses to agency inquiries.

· Provide expert leadership in innovative statistical methodology, including precision medicine approaches, responder analyses, adaptive designs, Bayesian methods, and emerging analytical strategies that support Kardigan’s development model.

· Serve as a trusted scientific and strategic partner to Clinical Development, Medical, Regulatory Affairs, and executive leadership, providing data-driven guidance on program strategy, statistical risk, trial feasibility, and critical portfolio decisions.

· Build, lead, and develop a high-performing Biostatistics organization, mentoring future leaders and establishing a culture of scientific excellence, accountability, innovation, and influence.

· Establish statistical standards, governance, quality systems, and submission-ready processes that ensure regulatory compliance, inspection readiness, and consistent analytical excellence across the portfolio.

· Oversee external statistical partners and CROs while maintaining scientific ownership, strategic oversight, and accountability for the quality and integrity of all statistical deliverables.

· Partner across the Biometrics organization and broader enterprise to strengthen evidence generation, support business development and due diligence activities, and help scale the function as Kardigan continues its growth trajectory.

Qualifications and Preferred Skills

Required:

· Ph.D. in Biostatistics, Statistics, or a closely related quantitative discipline.

· 15+ years of experience in pharmaceutical or biotechnology drug development, with substantial late-phase program experience.

· Demonstrated experience as the statistical lead or signatory on at least one NDA or BLA submission; must have been in the room, not only in a supporting role.

· Direct FDA interaction experience, including Type B or C meetings, statistical briefing documents, and responses to regulatory queries.

· Deep expertise in late-phase statistical methodology, including estimand frameworks, adaptive designs, surrogate endpoint validation, precision medicine and responder subgroup analysis, and multiplicity control.

· Bayesian methodology proficiency, including prior elicitation, posterior decision frameworks, and simulation-based design evaluation.

· Demonstrated ability to influence cross-functional leadership and program decisions through scientific expertise, credibility, and clarity of judgment.

· Proven track record of developing and elevating statistical talent in a team environment.

· Excellent verbal and written communication skills, with the ability to translate complex statistical concepts for technical, clinical, medical, regulatory, and executive audiences.

· Experience working in an environment where knowledge of and adherence to SOPs and regulatory guidelines are required.

Preferred:

· Cardiovascular or cardiometabolic clinical development experience.

· Experience with precision medicine frameworks, biomarker-driven trial design, and responder subgroup methodology in a regulatory submission context.

· Strong epidemiology or real-world data fluency, including observational study methodology and defining or refining target patient populations for precision-medicine-driven trials.

· Familiarity with digital health endpoints and novel data sources, including wearables or continuous monitoring approaches.

· External scientific presence through publications, conference presentations, professional society involvement, or KOL relationships in the cardiovascular or biostatistics community.

· Prior experience working in a small, fast-paced, high-growth biotechnology company.

Executive Search Profile

· Non-negotiable experience: Senior statistical leadership in late-phase development, hands-on NDA/BLA submission experience, and direct FDA engagement.

· Differentiating capabilities: Regulatory gravitas, precision medicine methodology depth, ability to influence clinical development strategy, and credibility with executive and scienti